NovaBiotics, the clinical stage antimicrobials drug discovery company, announces the rapid repurposing of Nylexa for the ‘hidden killer’ underlying COVID-19: secondary bacterial lung infections.  Nylexa ‘supercharges’ antibiotics, boosting their efficacy against...